- Home
- ZENV vs BTAI Comparison
ZENV vs BTAI Comparison
Compare ZENV & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZENV | BTAI |
|---|---|---|
| Founded | 2005 | 2017 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.3M | 43.7M |
| IPO Year | 2021 | 2018 |
Fundamental Metrics
Financial Performance| Metric | ZENV | BTAI |
|---|---|---|
| Price | $0.89 | $1.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $26.67 |
| AVG Volume (30 Days) | 33.7K | ★ 644.4K |
| Earning Date | 03-16-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $201,426,369.00 | $752,000.00 |
| Revenue This Year | $12.75 | N/A |
| Revenue Next Year | N/A | $265.60 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 24.80 | N/A |
| 52 Week Low | $0.86 | $1.17 |
| 52 Week High | $2.74 | $8.08 |
Technical Indicators
Market Signals| Indicator | ZENV | BTAI |
|---|---|---|
| Relative Strength Index (RSI) | 35.11 | 46.07 |
| Support Level | $0.86 | $1.85 |
| Resistance Level | $1.00 | $2.08 |
| Average True Range (ATR) | 0.05 | 0.15 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 26.95 | 42.45 |
Price Performance
Historical ComparisonAbout ZENV Zenvia Inc.
Zenvia Inc provides a platform that enables companies to create journeys for their end customers across a variety of channels. The company operates in two reportable segments namely CPaaS and SaaS. It has a geographic presence in Brazil, the USA, Argentina, Mexico, and Others. The company generates the majority of its revenue from Brazil.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.